Inclusion Criteria:

At time of diagnosis

- De novo multiple myeloma patients under 65 or in first relapse, in whom screening for
chromosome 13 deletion and beta2microglobulin assay have been performed.

- Salmon and Durie Stage: III, II, I with symptomatic bone lesion (radiological)

- Patient's written informed consent

- No clinical signs of heart failure or coronary insufficiency with LVEF>50%

- No hepatic in insufficiency: bilirubin<35μmol/l and SGOT, SGPT, alkaline phosphatase
less than 2.5 N

- No respiratory insufficiency: normal pulmonary function tests and DLCO>50%

- No pre-existing renal impairment not related to the disease

- No history of any other malignant disease with the exception of basal cell carcinoma
and stage I cervical cancer

- Negative HIV serology

- Effective contraception when justified

At the time of transplantation

- Good performance status (WHO score≤2)

- Creatinine≤170μmol/l and no ineligibility criteria for intensification

- Stem cells harvest ≥ 5x10E6 CD34/kg for 2 ASCT

- Absence of progressive disease before transplantation

Exclusion Criteria:

- Known refusal of the subject to participate to the study

- Female subject who is pregnant or breast-feeding

- History of allergy to any of the study medications, their analogues, or excipients in
the various formulations

- Main liver insufficiency

- ≥ Grade 3 peripheral neuropathy on clinical examination within 14 days before
enrollment